Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis

Journal of Neuroimmunology

Volumn 105, Issue 1, 2000, Pages 58-63

  Nelissen, Inge ^a   Vandenbroeck, Koen ^a   Fiten, Pierre ^a   Hillert, Jan ^b   Olsson, Tomas ^c   Giovanna Marrosu, Maria ^d   Opdenakker, Ghislain ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Dept Clin Neurosci Huddinge U ^*  (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Gelatinase B; HLA stratification; Microsatellite repeat; Multiple sclerosis; Polymorphism

Indexed keywords

GELATINASE B; MICROSATELLITE DNA;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

BASE SEQUENCE; FEMALE; HLA-DR ANTIGENS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICROSATELLITE REPEATS; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC;

EID: 0034213755     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00189-2     Document Type: Article

References (38)

1. Anthony D.C., Miller K.M., Fearn S., Townsend M.J., Opdenakker G., Wells G.M., Clements J.M., Chandler S., Gearing A.J., Perry V.H. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J. Neuroimmunol. 87:1998;62-72.
2. Chataway J., Feakes R., Coraddu F., Gray J., Deans J., Fraser M., Robertson N., Broadley S., Jones H., Clayton D., Goodfellow P., Sawcer S., Compston A. The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. Brain. 121:1998;1869-1887.
3. Cossins J.A., Clements J.M., Ford J., Miller K.M., Pigott R., Vos W., Van der Valk P., De Groot C.J. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 94:1997;590-598.
4. Croxton F.E. Elementary Statistics with Applications in Medicine. 1953;Prentice-Hall, New York. Chapter 14.
5. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1996;1194-1204.
6. Cuzner M.L., Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 94:1999;1-14.
7. Ebers G.C., Kukay K., et al. A full genome search in multiple sclerosis. Nat. Genet. 13:1996;472-476.
8. Epplen C., Jackel S., Santos E.J., D'Souza M., Poehlau D., Dotzauer B., Sindern E., Haupts M., Rude K.P., Weber F., Stover J., Poser S., Gehler W., Malin J.P., Przuntek H., Epplen J.T. Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann. Neurol. 41:1997;341-352.
9. Fiten P., Vandenbroeck K., Dubois B., Van Coillie E., Nelissen I., Van Damme J., Ligers A., Hillert J., Andersson M., Olsson T., Opdenakker G. Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development. J. Neuroimmunol. 95:1999;195-201.
10. Gijbels K., Galardy R.E., Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 94:1994;2177-2182.
11. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41:1992;29-34.
12. Gijbels K., Proost P., Masure S., Carton H., Billiau A., Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 36:1993;432-440.
13. Hewson A.K., Smith T., Leonard J.P., Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44:1995;345-349.
14. Hillert J. Genetics of multiple sclerosis. Handbook of Multiple Sclerosis. 1996;Marcel Dekker, New York.
15. Huhtala P., Tuuttila A., Chow L.T., Lohi J., Keski O.J., Tryggvason K. Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J. Biol. Chem. 266:1991;16485-16490.
16. Lee M.A., Palace J., Stabler G., Ford J., Gearing A., Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: A longitudinal clinical and MRI study. Brain. 122:1999;191-197.
17. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K.M., Hauser S.L., Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 121:1998;2327-2334.
18. Liedtke W., Cannella B., Mazzaccaro R.J., Clements J.M., Miller K.M., Wucherpfennig K.W., Gearing A.J., Raine C.S. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44:1998;35-46.
19. Linn R., Dupont B.R., Knight C.B., Plaetke R., Leach R.J. Reassignment of the 92-kDa type IV collagenase gene (CLG4B) to human chromosome 20. Cytogenet. Cell. Genet. 72:1996;159-161.
20. Maeda A., Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55:1996;300-309.
21. Marrosu M.G., Murru M.R., Costa G., Cucca F., Sotgiu S., Rosati G., Muntoni F. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am. J. Hum. Genet. 61:1997;454-457.
22. Martin R., Jaraquemada D., Flerlage M., Richert J., Whitaker J., Long E.O., McFarlin D.E., McFarland H.F. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 145:1990;540-548.
23. Matyszak M.K., Perry V.H. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J. Neuroimmunol. 69:1996;141-149.
24. McMillan W.D., Pearce W.H. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J. Vasc. Surg. 29:1999;122-129.
25. Norga K., Paemen L., Masure S., Dillen C., Heremans H., Billiau A., Carton H., Cuzner L., Olsson T., Van Damme J., Opdenakker G. Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Inflamm. Res. 44:1995;529-534.
26. Opdenakker G., Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol. Today. 15:1994;103-107.
27. Paemen L., Olsson T., Söderström M., Van Damme J., Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur. J. Neurol. 1:1994;55-63.
28. Pagenstecher A., Stalder A.K., Kincaid C.L., Shapiro S.D., Campbell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 152:1998;729-741.
29. Proost P., Van Damme J., Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 192:1993;1175-1181.
30. Sawcer S., Goodfellow P.N., Compston A. The genetic analysis of multiple sclerosis. Trends Genet. 13:1997;234-239.
31. Sawcer S., Jones H.B., Feakes R., Gray J., Smaldon N., Chataway J., Robertson N., Clayton D., Goodfellow P.N., Compston A. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet. 13:1996;464-468.
32. Shimajiri S., Arima N., Tanimoto A., Murata Y., Hamada T., Wang K.Y., Sasaguri Y. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 455:1999;70-74.
33. Spielman R.S., McGinnis R.E., Ewens W.J. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am. J. Hum. Genet. 52:1993;506-516.
34. St. Jean P.L., Zhang X.C., Hart B.K., Lamlum H., Webster M.W., Steed D.L., Henney A.M., Ferrell R.E. Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease. Ann. Hum. Genet. 59:1995;17-24.
35. Thomson G. Mapping disease genes: family-based association studies. Am. J. Hum. Genet. 57:1995;487-498.
36. Vandenbroeck K., Opdenakker G., Goris A., Murru R., Billiau A., Marrosu M.G. Interferon-γ gene polymorphism-associated risk for multiple sclerosis in Sardinia. Ann. Neurol. 44:1998;841-842.
37. Woolf B. On estimating the relation between blood group and disease. Ann. Hum. Genet. 19:1955;251-253.
38. Zhang B., Ye S., Herrmann S.-M., Eriksson P., de Maat M., Evans A., Arveiler D., Luc G., Cambien F., Hamsten A., Watkins H., Henney A.M. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 99:1999;1788-1794.